News | May 26, 2023
Lincoln Pharmaceuticals posts FY23 PAT at Rs. 72.90 Cr
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
With the on-going relentless efforts to imbibe new developments in ART, India will make significant progress in ensuring the best facilities and care for fertility to couples in India
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
The dividend cheque of Rs. 9.93 crore for the Ministry of Ayush was handed over to Sonowal
Sandoz is planned to be incorporated in Switzerland and to be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in the US
Active pharmaceutical ingredients revenue for the quarter was at Rs 913 crore
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
Company expects strong organic growth in sales, EBITDA in 2022
Subscribe To Our Newsletter & Stay Updated
